David Rosmarin

4.9k total citations · 2 hit papers
115 papers, 2.0k citations indexed

About

David Rosmarin is a scholar working on Dermatology, Immunology and Cell Biology. According to data from OpenAlex, David Rosmarin has authored 115 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Dermatology, 48 papers in Immunology and 47 papers in Cell Biology. Recurrent topics in David Rosmarin's work include melanin and skin pigmentation (45 papers), Dermatology and Skin Diseases (30 papers) and Atherosclerosis and Cardiovascular Diseases (18 papers). David Rosmarin is often cited by papers focused on melanin and skin pigmentation (45 papers), Dermatology and Skin Diseases (30 papers) and Atherosclerosis and Cardiovascular Diseases (18 papers). David Rosmarin collaborates with scholars based in United States, France and Germany. David Rosmarin's co-authors include Frederick A. Pereira, Adarsh V. Mudgil, Alice B. Gottlieb, Mark Lebwohl, Pedro Zancanaro, Nicole Dumont, John E. Harris, Amit G. Pandya, Kathleen Butler and Pearl E. Grimes and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David Rosmarin

105 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

2022 133 citations David Rosmarin, Thierry Passeron et al. profile →
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

2023 72 citations Andrew Blauvelt, Jacob P. Thyssen et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Rosmarin United States	21	920	610	540	443	387	115	2.0k
Richard S. Kalish United States	27	946 1.0×	803 1.3×	379 0.7×	138 0.3×	269 0.7×	56	2.2k
Matthias Bräutigam Germany	32	1.3k 1.4×	339 0.6×	409 0.8×	382 0.9×	302 0.8×	95	2.6k
Kiichiro Danno Japan	23	740 0.8×	349 0.6×	173 0.3×	218 0.5×	270 0.7×	100	1.7k
T. Ruzicka Germany	21	1.0k 1.1×	530 0.9×	125 0.2×	354 0.8×	210 0.5×	60	2.0k
Kazunari Sugita Japan	20	689 0.7×	879 1.4×	67 0.1×	162 0.4×	187 0.5×	98	1.9k
Magda Babina Germany	30	492 0.5×	1.6k 2.7×	183 0.3×	451 1.0×	148 0.4×	88	2.4k
Taina Hasan Finland	25	545 0.6×	508 0.8×	66 0.1×	429 1.0×	254 0.7×	38	1.3k
J Meynadier France	22	870 0.9×	586 1.0×	167 0.3×	182 0.4×	303 0.8×	109	1.6k
Sook Jung Yun South Korea	22	552 0.6×	162 0.3×	187 0.3×	156 0.4×	187 0.5×	148	1.5k
Rachel Grossman United States	15	607 0.7×	768 1.3×	137 0.3×	120 0.3×	145 0.4×	28	1.5k

Countries citing papers authored by David Rosmarin

Since Specialization

Citations

This map shows the geographic impact of David Rosmarin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Rosmarin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Rosmarin more than expected).

Fields of papers citing papers by David Rosmarin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Rosmarin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Rosmarin. The network helps show where David Rosmarin may publish in the future.

Co-authorship network of co-authors of David Rosmarin

This figure shows the co-authorship network connecting the top 25 collaborators of David Rosmarin. A scholar is included among the top collaborators of David Rosmarin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Rosmarin. David Rosmarin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosmarin, David, Amit G. Pandya, Thierry Passeron, et al.. (2025). Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatology and Therapy. 15(12). 3703–3716.

Harris, John E., Amit G. Pandya, Mark Lebwohl, et al.. (2024). Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: A Randomised Controlled Trial Secondary Analysis at 3 Years. SHILAP Revista de lepidopterología. 4(6). e404–e404. 7 indexed citations

Schneeweiss, Maria C., Robert J. Glynn, Richard Wyss, et al.. (2024). A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System. Journal of Investigative Dermatology. 145(5). 1070–1080. 6 indexed citations

Passeron, Thierry, Khaled Ezzedine, Iltefat Hamzavi, et al.. (2024). Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. EClinicalMedicine. 73. 102655–102655. 16 indexed citations

Rosmarin, David, et al.. (2024). Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location. Dermatology and Therapy. 14(6). 1633–1647. 6 indexed citations

Silverberg, Jonathan I., David Rosmarin, Raj Chovatiya, et al.. (2024). The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nature Communications. 15(1). 9230–9230. 12 indexed citations

Blauvelt, Andrew, Peter Foley, Richard G. Langley, et al.. (2024). Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 8(6). s437–s437.

Yosipovitch, Gil, Peter Lio, David Rosmarin, et al.. (2024). 497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology. 190(Supplement_2). ii6–ii7. 1 indexed citations

Wolkerstorfer, Albert, Thierry Passeron, David Rosmarin, et al.. (2023). PCR256 Correlation of Patient-Reported Vitiligo Noticeability Scale With Physician-Assessed Facial Vitiligo Area Scoring Index Responses: Post Hoc Analyses From the True-V Trials of Ruxolitinib Cream in Vitiligo. Value in Health. 26(12). S499–S499.

10.

Blauvelt, Andrew, Jacob P. Thyssen, Emma Guttman‐Yassky, et al.. (2023). Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. British Journal of Dermatology. 188(6). 740–748. 72 indexed citations breakdown →

11.

Harris, John E., David Rosmarin, Julien Sénéschal, et al.. (2023). 43912 Facial Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies. Journal of the American Academy of Dermatology. 89(3). AB48–AB48. 1 indexed citations

12.

Gordon, Kenneth B., Richard G. Langley, Richard B. Warren, et al.. (2023). Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. British Journal of Dermatology. 190(4). 477–485. 14 indexed citations

13.

Howell, Michael, Fiona Kuo, Kang Sun, et al.. (2023). Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream. SHILAP Revista de lepidopterología. 3(6). 100230–100230. 1 indexed citations

14.

Kolbinger, Frank, Franco Di Padova, Atul Deodhar, et al.. (2021). Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology & Therapeutics. 229. 107925–107925. 29 indexed citations

15.

Shrom, David, et al.. (2019). Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey. Dermatology and Therapy. 9(4). 785–797. 33 indexed citations

16.

Cork, Michael J., Lawrence F. Eichenfield, Andrew Blauvelt, et al.. (2019). 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology. 139(5). S104–S104. 1 indexed citations

17.

Lee, Nicole, et al.. (2018). Dupilumab as a Treatment for Allergic Contact Dermatitis. Dermatitis. 29(6). 347–348. 25 indexed citations

18.

Joshipura, Deep, et al.. (2018). Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B. Journal of the American Academy of Dermatology. 78(6). 1205–1207.e1. 58 indexed citations

19.

Rothstein, Brooke, Deep Joshipura, Ami Saraiya, et al.. (2017). 770 Treatment of vitiligo with topical janus kinase inhibitor ruxolitinib. Journal of Investigative Dermatology. 137(5). S132–S132. 1 indexed citations

20.

Rosmarin, David, Michelle Bush, & Pamela L. Scheinman. (2008). Patch testing a patient with allergic contact hand dermatitis who is taking infliximab. Journal of the American Academy of Dermatology. 59(1). 145–147. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact